Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels.
Thépot S, Malphettes M, Gardeur A, Galicier L, Asli B, Karlin L, Gérard L, Laumont R, Doize ML, Arnulf B, Fieschi C, Bengoufa D, Oksenhendler E. Thépot S, et al. Among authors: arnulf b. J Clin Immunol. 2010 Jul;30(4):602-6. doi: 10.1007/s10875-010-9417-2. J Clin Immunol. 2010. PMID: 20393788 Clinical Trial.
Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
Chandesris MO, Soulier J, Labaume S, Crinquette A, Repellini L, Chemin K, Malphettes M, Fieschi C, Asli B, Uzunhan Y, Fermand JP, Bories JC, Arnulf B. Chandesris MO, et al. Among authors: arnulf b. Br J Haematol. 2007 Feb;136(4):609-14. doi: 10.1111/j.1365-2141.2006.06479.x. Br J Haematol. 2007. PMID: 17223917 Free article.
Clinical and biological features of t(4;14) multiple myeloma: a prospective study.
Karlin L, Soulier J, Chandesris O, Choquet S, Belhadj K, Macro M, Bouscary D, Porcher R, Ghez D, Malphettes M, Asli B, Brouet JC, Bories JC, Hermine O, Fermand JP, Arnulf B. Karlin L, et al. Among authors: arnulf b. Leuk Lymphoma. 2011 Feb;52(2):238-46. doi: 10.3109/10428194.2010.537795. Epub 2011 Jan 24. Leuk Lymphoma. 2011. PMID: 21261498
Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy.
Szalat R, Arnulf B, Karlin L, Rybojad M, Asli B, Malphettes M, Galicier L, Vignon-Pennamen MD, Harel S, Cordoliani F, Fuzibet JG, Oksenhendler E, Clauvel JP, Brouet JC, Fermand JP. Szalat R, et al. Among authors: arnulf b. Blood. 2011 Oct 6;118(14):3777-84. doi: 10.1182/blood-2011-05-356907. Epub 2011 Jul 14. Blood. 2011. PMID: 21757618 Free article. Review.
The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
Bono C, Karlin L, Harel S, Mouly E, Labaume S, Galicier L, Apcher S, Sauvageon H, Fermand JP, Bories JC, Arnulf B. Bono C, et al. Among authors: arnulf b. Haematologica. 2012 Jul;97(7):1101-9. doi: 10.3324/haematol.2011.049981. Epub 2012 Jan 22. Haematologica. 2012. PMID: 22271897 Free PMC article.
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.
Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P, Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Fermand JP, Moreau P, Attal M, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome (IFM). Leleu X, et al. Among authors: arnulf b. Blood. 2015 Feb 26;125(9):1411-7. doi: 10.1182/blood-2014-11-612069. Epub 2015 Jan 9. Blood. 2015. PMID: 25575538 Free article. Clinical Trial.
173 results